The AMA passed a resolution to increase access to anti-obesity medications at its annual House of Delegates meeting.The resolution was championed by the Endocrine Society, according to a press release ...

In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

GLP-1 drugs such as Wegovy, Ozempic and Mounjaro are transforming weight loss and reshaping the food industry - driving ...

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

Haisco Pharmaceutical Group Co. Ltd. has disclosed compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...